Welcome to our dedicated page for Greenwich Lifesciences SEC filings (Ticker: GLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Greenwich LifeSciences, Inc. (GLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on corporate governance, auditor changes, shareholder voting outcomes, and other matters that complement the company’s clinical and regulatory news about GLSI-100 and the FLAMINGO-01 trial.
Form 8-K filings capture material events such as the July 24, 2025 change in independent registered public accounting firm from RBSM LLP to MaloneBailey LLP, including discussion of prior audit opinions, internal control material weaknesses referenced from the company’s periodic reports, and the absence of specified disagreements with the former auditor. Another 8-K dated December 18, 2025 reports the results of the 2025 Annual Meeting of Stockholders, detailing the election of directors and the ratification of MaloneBailey LLP as the auditor for the fiscal year ended December 31, 2025.
The DEF 14A definitive proxy statement for the 2025 Annual Meeting describes the proposals presented to stockholders, the record date, meeting logistics, and the matters subject to a vote, such as board elections and auditor ratification. Together, these filings outline how Greenwich LifeSciences manages shareholder meetings, voting procedures, and audit oversight while it advances its clinical program.
On Stock Titan, GLSI filings are paired with AI-powered tools that help summarize key points from lengthy documents, highlight important sections, and make it easier to understand topics like auditor changes, board composition, and voting results. Investors can use this page to quickly review Greenwich LifeSciences’ official statements, monitor governance developments over time, and connect these disclosures with the company’s ongoing work on GLSI-100 and the FLAMINGO-01 Phase III trial.